Skip to content

Novel Approaches to Reducing Tobacco Related Harm

Novel Approaches to Reducing Tobacco Related Harm Among HIV-Infected Smokers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02600273
Enrollment
18
Registered
2015-11-09
Start date
2017-01-31
Completion date
2019-06-30
Last updated
2020-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking, Smoking, Tobacco Smoking Behavior

Brief summary

The purpose of this study is to assess initial reactions to alternative nicotine/tobacco products among smokers living with HIV.

Detailed description

Participants will sample 4 alternative nicotine/tobacco products and provide initial reactions to the products.

Interventions

OTHERUsual brand cigarettes

Usual brand cigarettes

OTHERLower nicotine content cigarettes

SPECTRUM research cigarettes

OTHERElectronic cigarettes 1

Electronic cigarette with 0 g/mL e-liquid

OTHERElectronic cigarettes 2

Electronic cigarette with 18 g/mL e-liquid

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. HIV-infected adults age 18 and older currently receiving HIV care 2. Self-report smoking ≥10 cigarettes/day of a brand delivering \>0.5mg nicotine for \>2yrs 3. Have afternoon expired CO concentrations of ≥10ppm or morning urinary cotinine \>100ng/ml (as measured with NicAlert)

Exclusion criteria

1. Impaired mental status as assessed by observation 2. Acute intoxication as measured by breath alcohol level (BAL) \> 0 3. Current use of nicotine replacement or other pharmacotherapy for smoking cessation 4. Previous use of e-cigarettes 5. Use of other tobacco products (e.g., chew tobacco, cigars) on \> 10 of the past 30 days 6. Unstable HIV or associated comorbidities, as determined by a licensed medical professional. 7. Pregnancy (Females testing positive for pregnancy and any participants wishing to quit immediately will be referred to community smoking cessation treatment and will be excluded from the study) 8. Blood pressure at or above 160/100 or below 90/50 9. Heart rate at or above 105 bpm or below 45 bpm

Design outcomes

Primary

MeasureTime frameDescription
Subjective effects, as measured by surveywithin 2 minutes after sampling product(s)Satisfaction, acceptability, withdrawal, craving
Risk perceptions, as measured by surveyBefore and within 2 minutes after sampling product(s)Risk perceptions of products
Interest and confidence in quitting, as measured by surveywithin 2 minutes after sampling product(s)Interest and confidence in using and purchasing the tested products in the future

Secondary

MeasureTime frameDescription
Reinforcing properties of product(s), as measured by surveywithin 2 minutes after sampling product(s)Behavioral economics measures (commodity purchase task & cross-price elasticity)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026